Clin­i­cal, bio­chem­i­cal, and his­to­logic effects of intra-​articular admin­is­tra­tion of autol­o­gous con­di­tioned serum in horses with exper­i­men­tally induced osteoarthri­tis (pdf)

David D. Fris­bie, Christo­pher E. Kaw­cak, Natasha M. Werpy, Richard D. Park and C. Wayne McIlwraith

To assess the clin­i­cal, bio­chem­i­cal, and his­to­logic effects of intra-​articular admin­is­tra­tion of autol­o­gous con­di­tioned serum (ACS) in the treat­ment of exper­i­men­tally induced osteoarthri­tis in horses.

Effect of BMP-​12, TGF-​b1 and autol­o­gous con­di­tioned serum on growth fac­tor expres­sion in Achilles ten­don heal­ing (pdf)

Patri­cia E. Heis­ter­bach, Atanas Todorov, Rudolf Fluck­iger, Christo­pher H. Evans and Mar­tin Majewski

Achilles ten­don rup­tures are dev­as­tat­ing and recover slowly and incom­pletely. There is a great demand for bio­mol­e­c­u­lar ther­a­pies to improve recov­ery, yet lit­tle is under­stood about growth fac­tors in a heal­ing ten­don. Here, the role of growth fac­tors dur­ing ten­don heal­ing in a rat model and their reac­tion to sin­gle and mul­ti­ple growth fac­tor treat­ment are explored.

Accel­er­ated Heal­ing of the Rat Achilles Ten­don in Response to Autol­o­gous Con­di­tioned Serum (pdf)

Mar­tin Majew­ski, Peter E. Ochsner, Fan­jun Liu, Rudolf Fluck­iger and Christo­pher H. Evans

Despite advances in the treat­ment of rup­tured Achilles ten­don, imper­fec­tions of endoge­nous repair often leave patients symp­to­matic. Local admin­is­tra­tion of autol­o­gous con­di­tioned serum (ACS) in patients with inflam­ma­tory, degen­er­a­tive con­di­tions has shown ben­e­fi­cial effects.

Autol­o­gous Con­di­tioned Serum in the Treat­ment of Ortho­pe­dic Dis­eases (pdf)

Peter Wehling, Carsten Moser, David Fris­bie, C. Wayne McIl­wraith, Christo­pher E. Kaw­cak, Ruedi­ger Krauspe and Julio A. Reinec

The com­mon strate­gies for the treat­ment of patients with ortho­pe­dic dis­eases do not address the under­ly­ing patho­gen­e­sis. Sev­eral bio­log­i­cally based, local ther­a­pies aim­ing to influ­ence the cytokine imbal­ance are either in devel­op­ment or in the ini­tial stages of clin­i­cal use.

Auto­lo­gus interleukin-​1 recep­tor antag­o­nist improves func­tion and symp­toms in osteoarthri­tis when com­pared to placebo in prospec­tive ran­dom­ized con­trolled trial (pdf)

K.G. Auw Yang, N.J.H Rai­j­mak­ers, E.R.A. van Arkel, J.J. Caron, P.C. Rijk, W.J. Willems, A.J. Ver­bout, W.J.A. Dhert, D.B.F. Saris

Incu­ba­tion of blood with CrSO4-​coated glass beads stim­u­lates the synt­ge­sis of anti-​inflammatory cytokines, such as interleukin-​1 recep­tor antag­o­nist (Il-​1ra), IL-​5, IL-​10, and IL-​13, AS IL-​1ß is thought to play a key role in the devel­op­ment of osteoarthri­tis (OA), this prod­uct, also known as Orthokin, might be a viable treat­ment for symp­tomic knee OA in a ran­dom­ized, mul­ti­cen­tre, double-​blind, placebo-​controlled trial.